Bosutinib is a tyrosine kinase inhibitor (TKI) approved for the management of chronic myeloid leukemia (CML). TKIs are associated with pulmonary complications but are rarely described with bosutinib. Here, we report the first description of bosutinib-induced interstitial lung disease and pleural effusion, which resolved after the discontinuation of bosutinib.